newsfilter
← Latest News
Business Wire·

MyMD Pharmaceuticals® Advances Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy Lifespan

Sarcopenia trial shows no evidence of toxicity or safety issues and patients were enrolled in the next higher dose of MYMD-1 MyMD Pharmaceuticals, Inc.® (NASDAQ:MYMD) ("MyMD" or "the Company"), a clinical stage pharmaceutical company committed to de